New immune oncology drug molecules expected to result from leadXpro / InterAx partnership

Switzerland sits in a unique position. No other country possesses its concentration of biopharmaceutical capabilities across the entire value chain, from drug discovery through to commercialization. Its high innovative output and low domestic demand mean that continued success depends on an outlook that embraces international collaboration. Swiss biotechs are therefore the ideal partner, both for

From its European headquarters in Basel, Switzerland, BeiGene strategically collaborates with stakeholders worldwide to advance oncology research and development. It is commercially present in 40 countries and runs its clinical trials in over 45 countries.

Switzerland’s capital-rich investor base, strong financial system and leading industry know-how support the country’s vibrant biotech ecosystem, enabling companies to efficiently raise capital with a view to driving scientific discovery through to market launch. This benefits both local startups and global players in the life sciences sector. New requirements for sustainability reporting and i

Switzerland remains a steadfast driver of crucial scientific discoveries which support global healthcare innovation across many therapeutic areas and stages of product development, including diseases which have a major impact in the developing world. For over a decade Switzerland has ranked top in both the Global Innovation Index and INSEAD’s Global Talent Index, but much of its success can be a

Global supply networks must be strengthened and made more resilient in order to ensure an uninterrupted supply of essential medicines and everyday goods. Swiss life sciences companies contribute to this on several levels, from investments in R&D to international cooperation and sustainable production for global markets. Improvements in Switzerland’s framework conditions could further support